Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 3
2009 5
2010 3
2011 7
2012 10
2013 4
2014 3
2015 2
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

33 results
Results by year
Filters applied: . Clear all The following terms were not found in PubMed: NCT00352898, NCT01874457, NCT00388440, NCT00985166, NCT00822237, NCT00313950, NCT00488683, NCT00156559, NCT00000815, NCT00985153, NCT00310856, NCT00984295, NCT00101816, NCT00101647, NCT00148941, NCT00192166, NCT00263692, NCT00314041, NCT00258895, NCT00483574
Page 1
Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.
Müller MC, Cortes JE, Kim DW, Druker BJ, Erben P, Pasquini R, Branford S, Hughes TP, Radich JP, Ploughman L, Mukhopadhyay J, Hochhaus A. Müller MC, et al. Blood. 2009 Dec 3;114(24):4944-53. doi: 10.1182/blood-2009-04-214221. Epub 2009 Sep 24. Blood. 2009. PMID: 19779040 Free PMC article.
All trials were registered at http://www.clinicaltrials.gov as NCT00123474, NCT00101660, and NCT00103844....
All trials were registered at http://www.clinicaltrials.gov as NCT00123474, NCT00101660, and NCT00103844....
Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.
Snape MD, Perrett KP, Ford KJ, John TM, Pace D, Yu LM, Langley JM, McNeil S, Dull PM, Ceddia F, Anemona A, Halperin SA, Dobson S, Pollard AJ. Snape MD, et al. JAMA. 2008 Jan 9;299(2):173-84. doi: 10.1001/jama.2007.29-c. JAMA. 2008. PMID: 18182599 Clinical Trial.
CONCLUSION: MenACWY is well tolerated and immunogenic in infancy. Trial Registration clinicaltrials.gov Identifier: NCT00262002....
CONCLUSION: MenACWY is well tolerated and immunogenic in infancy. Trial Registration clinicaltrials.gov Identifier: NCT00262002....
Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (M-M-RvaxPro) and a varicella vaccine (VARIVAX) by intramuscular or subcutaneous routes at separate injection sites: a randomised clinical trial.
Gillet Y, Habermehl P, Thomas S, Eymin C, Fiquet A. Gillet Y, et al. BMC Med. 2009 Apr 14;7:16. doi: 10.1186/1741-7015-7-16. BMC Med. 2009. PMID: 19366435 Free PMC article. Clinical Trial.
Integration of both administration routes in the current European indications for the two vaccines will now allow physicians in Europe to choose their preferred administration route in routine clinical practice. TRIAL REGISTRATION: ClinicalTrials.gov NCT00432523....
Integration of both administration routes in the current European indications for the two vaccines will now allow physicians in Europe to ch …
The safety profile of Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine (HibMenCY).
Rinderknecht S, Bryant K, Nolan T, Pavia-Ruz N, Doniz CA, Weber MA, Cohen C, Aris E, Mesaros N, Miller JM. Rinderknecht S, et al. Hum Vaccin Immunother. 2012 Mar;8(3):304-11. doi: 10.4161/hv.18752. Epub 2012 Feb 13. Hum Vaccin Immunother. 2012. PMID: 22327493 Free PMC article.
These studies are registered at www.clinicaltrials.gov NCT00345579 (primary vaccination study), NCT00345683 (fourth dose vaccination study) and NCT00289783 (primary and fourth dose vaccination studies)....
These studies are registered at www.clinicaltrials.gov NCT00345579 (primary vaccination study), NCT00345683 (fourth dose vaccination …
Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.
Knuf M, Zepp F, Helm K, Maurer H, Prieler A, Kieninger-Baum D, Douha M, Willems P. Knuf M, et al. Eur J Pediatr. 2012 Mar;171(3):463-70. doi: 10.1007/s00431-011-1569-4. Epub 2011 Sep 21. Eur J Pediatr. 2012. PMID: 21935584 Clinical Trial.
CONCLUSION: Immunogenicity of the combined MMRV vaccine was sustained 3 years post-vaccination. (208136/041/NCT00406211)....
CONCLUSION: Immunogenicity of the combined MMRV vaccine was sustained 3 years post-vaccination. (208136/041/NCT00406211)....
Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines.
Vesikari T, Forsten A, Bianco V, Van der Wielen M, Miller JM. Vesikari T, et al. Pediatr Infect Dis J. 2015 Dec;34(12):e298-307. doi: 10.1097/INF.0000000000000897. Pediatr Infect Dis J. 2015. PMID: 26780033 Clinical Trial.
METHODS: This phase III, open-label, controlled study in Finland (NCT00955682) enrolled children previously randomized (3:1) at 12-23 months (NCT00474266) to receive 1 dose of MenACWY-TT or MenC conjugate vaccine (MenC-CRM197). ...
METHODS: This phase III, open-label, controlled study in Finland (NCT00955682) enrolled children previously randomized (3:1) at 12-23 months …
An open-label, randomized, multi-center study of the immunogenicity and safety of DTaP-IPV (Kinrix™) co-administered with MMR vaccine with or without varicella vaccine in healthy pre-school age children.
Klein NP, Weston WM, Kuriyakose S, Kolhe D, Howe B, Friedland LR, Van Der Meeren O. Klein NP, et al. Vaccine. 2012 Jan 11;30(3):668-74. doi: 10.1016/j.vaccine.2011.10.065. Epub 2011 Nov 4. Vaccine. 2012. PMID: 22064267 Clinical Trial.
This study was undertaken to evaluate the immunogenicity and reactogenicity of Kinrix when co-administered with MMR (M-M-RII(), Merck & Co.) and Varivax (Merck & Co.) in 4-6 year old children. METHODS: Phase IIIb, open-label, non-inferiority study (NCT00871117). We …
This study was undertaken to evaluate the immunogenicity and reactogenicity of Kinrix when co-administered with MMR (M-M-RII(), Merck & …
Immunogenicity and safety of combined measles-mumps-rubella-varicella vaccine using new measles and rubella working seeds in healthy children in Taiwan and Singapore: a phase II, randomized, double-blind trial.
Huang LM, Lee BW, Chan PC, Povey M, Henry O. Huang LM, et al. Hum Vaccin Immunother. 2013 Jun;9(6):1308-15. doi: 10.4161/hv.24035. Epub 2013 Feb 20. Hum Vaccin Immunother. 2013. PMID: 23425607 Free PMC article. Clinical Trial.
AIM: This study evaluated the immunogenicity and safety of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine produced with measles and rubella monovalent bulks derived from a newly established working seed virus stock (MMRV(new WS)) compared with the combined MMRV vaccin …
AIM: This study evaluated the immunogenicity and safety of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine produced with measles …
Booster vaccination of pre-school children with reduced-antigen-content diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine co-administered with measles-mumps-rubella-varicella vaccine: a randomized, controlled trial in children primed according to a 2 + 1 schedule in infancy.
Ferrera G, Cuccia M, Mereu G, Icardi G, Bona G, Esposito S, Marchetti F, Messier M, Kuriyakose S, Hardt K. Ferrera G, et al. Hum Vaccin Immunother. 2012 Mar;8(3):355-62. doi: 10.4161/hv.18650. Epub 2012 Feb 13. Hum Vaccin Immunother. 2012. PMID: 22327497 Free PMC article. Clinical Trial.
Booster vaccination for pre-school children has been recommended in Italy since 1999. In this study (NCT00871000), the immunogenicity, safety and reactogenicity of a booster dose of reduced-antigen content diphtheria-tetanus-acellular pertussis-inactivated poliovirus vacci …
Booster vaccination for pre-school children has been recommended in Italy since 1999. In this study (NCT00871000), the immunogenicity …
Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial.
Vesikari T, Karvonen A, Bianco V, Van der Wielen M, Miller J. Vesikari T, et al. Vaccine. 2011 Jun 6;29(25):4274-84. doi: 10.1016/j.vaccine.2011.03.043. Epub 2011 Apr 6. Vaccine. 2011. PMID: 21443965 Clinical Trial.
ACWY-TT can be co-administered with MMRV without affecting immunogenicity or safety profiles of either vaccine. This study has been registered at www.clinicaltrials.gov NCT00474266....
ACWY-TT can be co-administered with MMRV without affecting immunogenicity or safety profiles of either vaccine. This study has been register …
33 results